
APPENDIX A

Table A1: Patient characteristics before and after propensity score reweighting in SCHOLAR-1

| Figure |  | ZUMA-1  (N = 111) | SCHOLAR-1  (N = 521) | % bias | p>t |
| --- | --- | --- | --- | --- | --- |
| Age (years) | Unweighted | 56.2 | 52.8 | 27.4 | 0.010 |
|  | Re-weighted | 55.9 | 57.9 | -16.1 | 0.217 |
| Sex: Male | Unweighted | 69.4% | 64.4% | 10.5 | 0.322 |
|  | Re-weighted | 68.5% | 66.7% | 3.9 | 0.773 |
| Stage: III-IV | Unweighted | 84.7% | 68.2% | 39.5 | 0.001 |
|  | Re-weighted | 84.3% | 72.1% | 29.1 | 0.088 |
| Diagnosis: PMBCL | Unweighted | 8.1% | 1.9% | 28.6 | <0.001 |
|  | Re-weighted | 8.3% | 5.6% | 12.8 | 0.424 |
| Diagnosis: TFL | Unweighted | 18.9% | 3.6% | 49.6 | <0.001 |
|  | Re-weighted | 16.7% | 18.5% | -6.0 | 0.722 |
| Relapsed post-SCT: | Unweighted | 19.8% | 26.0% | -14.7 | 0.172 |
|  | Re-weighted | 20.4% | 23.1% | -6.6 | 0.623 |
| **Key:** SCT, stem cell transplant; PMBCL, primary mediastinal B-cell lymphoma; TFL, transformed follicular lymphoma.  **Note:** The full intent-to-treat population (N = 111) from ZUMA-1 was used as the largest sample of baseline characteristics in the population of interest. | | | | | |

Figure A1: Overall survival for SCHOLAR-1 population: before and after propensity score reweighting



**Key:** OS, overall survival.